Evidence map›Paper›PMID 39819421›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Microbially produced imidazole propionate impairs prostate cancer progression through PDZK1.

Shengkai Jin, Yuhua Zhou, Jing Lv, Yichen Lu, Yuwei Zhang, Menglu Li, Ninghan Feng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shengkai Jin *Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Yuhua Zhou *Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Jing Lv *Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Yichen LuNanjing Medical University, Nanjing, 211166, China.
Yuwei ZhangNantong University Medical School, 9 Qiangyuan Road, Nantong, 226019, China. zhangyw0123@njmu.edu.cn.
Menglu LiDepartment of Urology, Jiangnan University Medical School, Jiangnan University Medical Center (Wuxi No. 2 People's Hospital), 68 Zhongshan Road, Wuxi, 214002, Jiangsu, China. lmlbw1232@163.com.
Ninghan FengWuxi School of Medicine, Jiangnan University, Wuxi, 214122, China. n.feng@jiangnan.edu.cn.

Funding

Major Project of Jiangsu Commission of Health: Basic research and clinical application of biomarkers for early diagnosis of prostate cancer ZD2021002National Natural Science Foundation of China 82302654National Natural Science Foundation of China 82370777National Natural Science Foundation of Jiangsu Province SBK2023044153Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX24_3596"San Ming" Strategic Talent Project of Wuxi Municipal Health Commission HB2023032Science and Technology Research Project of Wuxi Science and Technology Bureau K20221029
6 · The paper itself

Abstract

backgroundA close relationship exists between castration-resistant prostate cancer (CRPC) and histidine metabolism by gut microbes. However, the effects of the histidine metabolite imidazole propionate (IMP) on prostate cancer (PCa) and its underlying mechanisms are not well understood.

methodsWe first assessed the effects of IMP on cell proliferation and migration at the cellular level. Subsequently, we investigated the mechanism of action of IMP using transcriptome sequencing, qPCR, and Western blot analysis. Finally, we validated our findings in vivo using a mouse model.

resultsHistidine had no effect on PCa cell proliferation; however, IMP significantly inhibited the proliferation and migration of PC3 and DU145 cells. Mechanistic studies indicate that IMP exerts its effects by upregulating PDZK1 expression, which subsequently inhibits the phosphorylation of the PI3K-AKT pathway.

conclusionsIn conclusion, IMP significantly inhibits the progression of PCa, offering new insights into potential treatments for CRPC.

Indexed as

ImidazolesPropionatesProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAnimalsCell Line, TumorCell MovementCell ProliferationDisease Models, AnimalDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktImidazolesPhosphatidylinositol 3-KinasesPropionatesProto-Oncogene Proteins c-aktCastration-resistant prostate cancerHistidineImidazole propionateMicrobiomeProstate cancer

Identifiers

PMID39819421
PMCPMC11740605

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.